
NXTC
NextCure Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.420
Open
5.760
VWAP
--
Vol
3.62M
Mkt Cap
16.51M
Low
5.3101
Amount
--
EV/EBITDA(TTM)
--
Total Shares
27.97M
EV
-39.35M
EV/OCF(TTM)
--
P/S(TTM)
--
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Show More
3 Analyst Rating

45.87% Upside
Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 9.00 USD with a low forecast of 3.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy

45.87% Upside
Current: 6.170

Low
3.00
Averages
9.00
High
15.00

45.87% Upside
Current: 6.170

Low
3.00
Averages
9.00
High
15.00
Piper Sandler
Edward Tenthoff
Overweight
downgrade
$36 -> $15
2025-07-15
Reason
Piper Sandler
Edward Tenthoff
Price Target
$36 -> $15
2025-07-15
downgrade
Overweight
Reason
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on NextCure to $15 from $36 and keeps an Overweight rating on the shares. The firm notes NextCure exercised a 12-for-1 reverse stock split effective July 14th. Piper estimates NextCure now has 2.338 million shares outstanding and trades at an $11.5M market cap.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$3
2025-03-17
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$3
2025-03-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$4 → $3
2025-03-07
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$4 → $3
2025-03-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$8 → $4
2024-11-11
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$8 → $4
2024-11-11
Maintains
Strong Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$4
2024-08-02
Reason
Needham
Gil Blum
Price Target
$4
2024-08-02
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for NextCure Inc (NXTC.O) is -0.32, compared to its 5-year average forward P/E of -1.64. For a more detailed relative valuation and DCF analysis to assess NextCure Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.64
Current PE
-0.32
Overvalued PE
-0.31
Undervalued PE
-2.98
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.15
Undervalued EV/EBITDA
-0.07
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-30.29%
-10.99M
Operating Profit
FY2025Q1
YoY :
-35.84%
-10.98M
Net Income after Tax
FY2025Q1
YoY :
-36.07%
-0.39
EPS - Diluted
FY2025Q1
YoY :
+2.78%
-12.99M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
882.4K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NXTC News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
18:07:39
NextCure presents new preclinical data on osteogenesis imperfecta treatment

2025-06-16 (ET)
2025-06-16
07:17:58
NextCure, Simcere Zaiming announce strategic partnership

2025-05-01 (ET)
2025-05-01
16:39:56
NextCure reports Q1 EPS (39c), consensus (40c)

Sign Up For More Events
Sign Up For More Events
News
9.0
07-25NASDAQ.COMPinnedNextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate
4.5
07-25BenzingaUS Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
9.5
07-25BenzingaWhy Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch

HUSA
Houston American Energy Corp
10.860
USD
-2.95%

BOSC
BOS Better Online Solutions Ltd
5.030
USD
+1.00%

NAAS
NaaS Technology Inc
0.678
USD
+1.80%

DRCT
Direct Digital Holdings Inc
0.556
USD
+2.77%

TENX
Tenax Therapeutics Inc
6.050
USD
-0.98%

GREE
Greenidge Generation Holdings Inc
1.730
USD
-6.99%

ERNA
Ernexa Therapeutics Inc
1.950
USD
-7.14%

RVSN
Rail Vision Ltd
0.371
USD
-7.49%

GDC
GD Culture Group Ltd
3.320
USD
-3.21%

DATS
DatChat Inc
2.580
USD
-3.01%
FAQ

What is NextCure Inc (NXTC) stock price today?
The current price of NXTC is 6.17 USD — it has increased 17.3 % in the last trading day.

What is NextCure Inc (NXTC)'s business?

What is the price predicton of NXTC Stock?

What is NextCure Inc (NXTC)'s revenue for the last quarter?

What is NextCure Inc (NXTC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for NextCure Inc (NXTC)'s fundamentals?

How many employees does NextCure Inc (NXTC). have?
